OTTAWA, Feb. 18 /PRNewswire-FirstCall/ -- It was announced today that Medizone International's (Pink Sheets: MZEI) AsepticSure(TM) hospital sterilization system is being developed under the direction of Dr. Michael E. Shannon of the Canadian Foundation for Global Health. Dr. Shannon was recently appointed President of the Canadian Foundation for Global Health. He also serves as a board member of Medizone International and is the Company's Director of Medical Affairs.
The Medizone AsepticSure(TM) system is described as a portable decontamination and sterilization system for hospitals, government buildings, schools and other functionally critical environments that might currently require, or need to be prepared for, countermeasures capability from contamination by infectious biological agents such as C difficile, E coli, Pseudomonas aeruginous, MRSA and VRE. The AsepticSure(TM) system is designed to sterilize the space and then return it to full service in two hours or less.
Dr. Shannon stated that "this research partnership is the first for the Foundation and he expects that it will establish a model for other projects in the future. Presently, the Foundation is fully occupied in developing this sterilization program. We are currently identifying principal investigators as well as a suitable research institution at which we plan to focus most of our microbiology for this exciting project. Our intention is to begin independent university trials in the spring with the goal of validating the effectiveness of our new system across a broad range of bacterial and viral pathogens. This will be quickly followed by actual hospital beta testing to confirm the practicability of our decontamination protocols. Based upon innovative new engineering approaches, we remain confident that this research will reliably demonstrate 5 log reductions for most, if not all, of these often fatal bacteria. The implications of such work are indeed profound as these pathogens are considered to be the main causative agents of hospital derived infections and collectively account for tens of thousands of lives lost each year in the US alone. So far we have received a high level of interest from hospitals in both the United States and Canada and expect that if the university trials are as successful as we anticipate, it will be a smooth transition to hospital beta testing of the prototype design which is expected to begin during the 3rd quarter of 2009."
The Canadian Foundation for Global Health is a federally chartered not for profit Canadian Corporation. It has been established to assist in the research and development of novel and advanced emerging technologies in the field of science and medicine deemed to be of benefit to humanity.
Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to decontaminate and sterilize hospital surgical suites, emergency rooms and intensive care units.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact for the Canadian Foundation for Global Health 613-231-8555
Investor Relations, Medizone International: 800-953-3350 /
web site: www.medizoneint.com
|SOURCE Medizone International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved